Neoadjuvant strategy as initial treatment in resectable pancreatic cancer: concrete evidence of benefit

Anticancer Res. 2014 Sep;34(9):4673-6.


Pancreatoduodenectomy remains the recommended treatment in potentially curative strategies for pancreatic carcinoma. Due to high local failure rates even after complete resection, a multi-modality treatment approach is paramount in the management of resectable disease. Despite there being insufficient evidence to recommend a specific neoadjuvant strategy, several studies have tested the use of preoperative chemoradiotherapy in this sub-group of patients, achieving promising results. The treatment is well-tolerated, with higher rates of negative margins and lower rates of lymph node positivity at resection, a decrease in local failure and benefit in overall survival. Considering the poor oncological results after primary surgical treatment, neoadjuvant strategy should be considered as a valid alternative in resectable pancreatic carcinoma.

Keywords: Pancreas; neoadjuvant treatment; pancreatic cancer; review.

Publication types

  • Review

MeSH terms

  • Chemoradiotherapy
  • Evidence-Based Medicine
  • Humans
  • Neoadjuvant Therapy*
  • Neoplasm Staging
  • Pancreatic Neoplasms / mortality
  • Pancreatic Neoplasms / pathology
  • Pancreatic Neoplasms / surgery
  • Pancreatic Neoplasms / therapy*
  • Pancreaticoduodenectomy
  • Treatment Outcome